Head-to-head evidence
GW642444M vs Salbutamol HFA-134a
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
GW642444M
Developed by GlaxoSmithKline
NCT00600171 · Phase 2 · completed
The study was randomized and double-blind, compared five GW642444M doses with placebo, and included 614 randomized participants. Its primary lung-function endpoint was a surrogate measure rather than a direct clinical outcome, and the results were mixed across doses: the 12.5, 25, and 50 microgram doses outperformed placebo, while the 3 and 6.25 microgram doses did not.
Salbutamol HFA-134a
Developed by GlaxoSmithKline
NCT06261957 · Phase 3 · completed
The study randomized 477 adults and used quadruple blinding with an active salbutamol comparator. Its primary endpoint was the number of participants with adverse events, but no results or statistical comparison are posted, so the outcome is currently unknown.
Next expected readout: February 2027 · NCT06433921 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GW642444M's landscape · Salbutamol HFA-134a's landscape